Pharmaceuticals, Biotechnology and Life Sciences
Myovant Sciences (NYSE: MYOV) and Pfizer (NYSE: PFE) have announced an update on the Supplemental New Drug Application (sNDA) for MYFEMBREE (relugolix 40 mg, estradiol 1 mg and norethindrone acetate 0.5 mg) for the management of moderate to severe pain associated with endometriosis.
Jeito Capital (“Jeito”), a leading independent Private Equity firm dedicated to biotech and biopharma, announced today that it has co-led a $76 million Series A financing round in CDR-Life, a privately-held biotech company developing a new generation of immuno-oncology therapies.
Scilex Holding Company (“Scilex”), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a…
IO Biotech, a clinical-stage biopharmaceutical company has dosed the first patient, in metastatic non-small cell lung cancer (NSCLC), in its…
FDA has placed on clinical hold Ocugen’s phase 2/3 study for COVAXIN.
CHAPEL HILL, N.C.–(BUSINESS WIRE)–Renovion today announced that Dr. Martin “Marty” Zamora, MD, has joined Renovion as Chief Medical Officer. Dr.…
Surf Bio, Inc., a biopharmaceutical company commercializing a novel drug stabilization platform, today announced a $16 million Series Seed round…
Design Pharmaceuticals, a company redesigning small molecule drug discovery, has announced the closing of a pre-series A round of $5 million, including an investment of $3 million from Virtus Inspire Venture Partners. The proceeds will be used to further build the company’s discovery platform and operations.
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) and Immedica Pharma AB (“Immedica”)have entered a license and supply agreement for Iomab-B, an Antibody Radiation Conjugate comprised of apamistamab, a CD45 targeting antibody, and the radioisotope iodine-131 that is being developed for targeted conditioning to facilitate bone marrow transplant (BMT) and other cell and gene therapies.
Bristol Myers Squibb (NYSE: BMY) has announced results from the Phase 3 CheckMate -816 trial, which showed that neoadjuvant treatment with three cycles of Opdivo (nivolumab) in combination with chemotherapy significantly improved event-free survival (EFS), a primary endpoint, compared to chemotherapy alone in patients with resectable non-small cell lung cancer (NSCLC).